In the meantime, Hikma and Ventura are due to hear back from the FDA by 10 May on whether their generic Advair has been approved. Analysts said that the Mylan rejection should be seen as a short ...

The main patent on Advair (fluticasone+salmeterol ... Novartis’ Sandoz generics arm, and Hikma have tried unsuccessfully to get copies approved, and the regulator had rejectedMylan’s generic ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.